Concepedia

Prospective, randomized trial comparing cetrorelix acetate and ganirelix acetate in a programmed, flexible protocol for premature luteinizing hormone surge prevention in assisted reproductive technologies

J. Wilcox, Daniel Potter, Marva Moore, Lee Ferrande, Eduardo Kelly

Fertility and Sterility · 2005 · 50 citations · 23 references

DOIFull text

Open access

Concepts

References

23

Reduced in‐vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phase

James Stanger, John L. Yovich · BJOG An International Journal of Obstetrics & Gynaecology · 1985 · 384 citations

, , +19

Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial

Human Reproduction · 2000 · 374 citations · Full text

Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin

Carola Albano, R. Felberbaum, Johan Smitz et al. · Human Reproduction · 2000 · 310 citations · Full text

Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation

K. Diedrich, C. Diedrich, Eduarda M. Santos et al. · Human Reproduction · 1994 · 310 citations

A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group

Human Reproduction · 1998 · 290 citations · Full text

, , +16